http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e863e8ef9959503e609339333914781f
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Mita C. Mita |
| name | Alain C. Mita Alain C Mita |
| given-name | Alain Alain C. Alain C |
| organization-name | Samuel Oschin Comprehensive Cancer Institute, Cedars‐Sinai Medical Center Los Angeles California USA; Department of Medical Oncology Cedars‐Sinai Medical Center Los Angeles California USA Authors' Affiliations: 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts; 2Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; 3University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium; 4Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 5Novartis Pharmaceutical Corporation, East Hanover, New Jersey; 6Ventana Medical Systems, Inc., Tucson, Arizona; and 7Seconda Università di Napoli, Naples, Italy Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles, CA, USA; Department of Medical Oncology, Cedars-Sinai Medical Center , Los Angeles, CA, USA Samuel Oschin Comprehensive Cancer Institute Cedars‐Sinai Medical Center Los Angeles California U.S.A.; Department of Medical Oncology Cedars‐Sinai Medical Center Los Angeles California U.S.A. 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, San Antonio, Texas and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California; Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California 16Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas. Samuel Oschin Comprehensive Cancer Institute Cedars‐Sinai Medical Center Los Angeles California From the Institute for Drug Development at the Cancer Therapy and Research Center; Nuclear Medicine Department, The University of Texas Health Science Center, San Antonio, TX; Indiana University Cancer Center; and Eli Lilly and Company, Indianapolis, IN. 2Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas; Authors' Affiliation: Cedars-Sinai Medical Center, Los Angeles, California 1Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center; Samuel Oschin Comprehensive Cancer Institute Cedars‐Sinai Medical Center Los Angeles California; Department of Medical Oncology Cedars‐Sinai Medical Center Los Angeles California 2Cedars-Sinai Medical Center, Los Angeles, California. Authors' Affiliations: 1Vall d'Hebron Institut d'Oncologia and Universitat Autonoma of Barcelona, Barcelona, Spain; 2University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; 3University of Leicester, Leicester, United Kingdom; 4University Hospital of Zürich, Zürich, Switzerland; 5Memorial Sloan-Kettering Cancer Center, New York, New York; 6Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; 7Novartis Institutes for BioMedical Research, Cambridge, Massachusetts; and 8Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 1Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California. CTRC at the University of Texas Health Science Center San Antonio Texas Authors' Affiliations: 1South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, Texas; 2Indiana University Simon Cancer Center, Indianapolis, Indiana; 3Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas; 4Adnexus, A Bristol-Myers Squibb R&D Company, Waltham, Massachusetts; and 5Bristol-Myers Squibb, Princeton, New Jersey Authors' Affiliations: 1Institute for Drug Development, San Antonio, Texas; 2Karmanos Cancer Institute, Detroit, Michigan; and 3Amgen, Inc., Thousand Oaks, California Samuel Oschin Comprehensive Cancer Institute Helsinki University Hospital, University of Helsinki Helsinki Finland; Division of Medical Oncology, Department of Medicine Cedars‐Sinai Medical Center Los Angeles California USA Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital,... University of Texas Health Science Center, San Antonio, TX Authors' Affiliation: Institute for Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, Texas Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA From the Cancer Therapy and Research Center, Institute for Drug Development; The University of Texas Health Science Center, San Antonio, TX; Cognigen Corp, Buffalo, NY; and ARIAD Pharmaceuticals Inc, Cambridge MA Authors' Affiliation: Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, Texas Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California Samuel Oschin Comprehensive Cancer Institute Cedars‐Sinai Medical Center Los Angeles California; Division of Medical Oncology Department of Medicine Cedars‐Sinai Medical Center Los Angeles California Authors' Affiliations: 1Institute for Drug Development, San Antonio, Texas; 2Nereus Pharmaceuticals, Inc., San Diego, California; 3Northwest Medical Specialties, Tacoma, Washington; 4Karmanos Cancer Institute, Detroit, Michigan; and 5VirtualScopics, Inc., Rochester, New York 3Cedars-Sinai Medical Center, Los Angeles, California. Authors' Affiliations: 1Premiere Oncology, Santa Monica, California; 2Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee; 3Amgen Inc., Thousand Oaks, California; and 4Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 1Experimental Therapeutics, Cedars-Sinai, Los Angeles, California. 3Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas; |
Incoming Links
Total number of triples: 102.